A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma

PURPOSE: The rearrangement of ROS1 (C-ros oncogene 1) is an important driver of non-small cell lung cancer (NSCLC). Currently, only approximately 24 ROS1 fusion partners have been shown to be sensitive to crizotinib. Although fusion partner determination is not required to treat patients with tyrosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Shaowei, Li, Hui, Liu, Ying, Xu, Jinhua, Huang, Zhicheng, Yan, Shi, Zhang, Qiang, Cheng, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667179/
https://www.ncbi.nlm.nih.gov/pubmed/33204104
http://dx.doi.org/10.2147/OTT.S278907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667179/
https://www.ncbi.nlm.nih.gov/pubmed/33204104
http://dx.doi.org/10.2147/OTT.S278907

Ejemplares similares